Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CCL5 | P13501 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10232864 | 1.00 | EPHX2 (0.41) | EPHX2MEN1KMT2AJAK2JAK1 | |
| SCHEMBL20756318 | 0.89 | MEN1 (0.44) | EPHX2MEN1KMT2AJAK2JAK1 | |
| SCHEMBL2603251 | 0.88 | EPHX2 (0.46) | EPHX2MEN1KMT2AJAK2JAK1 | |
| SCHEMBL23261695 | 0.87 | EPHX2 (0.44) | EPHX2MEN1KMT2AJAK2JAK1 | |
| SCHEMBL23126815 | 0.85 | EPHX2 (0.39) | EPHX2MEN1KMT2AJAK2JAK1 | |
| SCHEMBL26145129 | 0.85 | EPHX2 (0.39) | EPHX2MEN1KMT2AJAK2JAK1 | |
| SCHEMBL17755705 | 0.83 | EPHX2 (0.34) | EPHX2MEN1KMT2ACCL5CCR5 | |
| SCHEMBL13368879 | 0.82 | TSHR (0.44) | MEN1KMT2A | |
| SCHEMBL10232861 | 0.82 | L3MBTL1 (0.38) | EPHX2LMNA | |
| SCHEMBL12384515 | 0.82 | TSHR (0.44) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2019-09-26 | — | — | US | disclosed |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK7, CDK3, CDK17 | EPHX2 2688/4885MEN1 671/4885KMT2A 1580/4885 |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | CDK7, CDK6, CDK3 | EPHX2 3769/4885MEN1 1073/4885KMT2A 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.